HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

margatoxin

isolated from the scorpion Centruroides margaritatus; a potassium channel blocker

Also Known As:

MGTX; potassium channel toxin alpha-ktx 2.2

Networked: 25 relevant articles (3 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Venoms: 4328
  - Arthropod Venoms: 770
    - Scorpion Venoms: 373
      - margatoxin: 25
Biological Factors: 2472
- Biological Toxins: 20
  - Venoms: 4328
    - Arthropod Venoms: 770
      - Scorpion Venoms: 373
        margatoxin: 25

Experts

1.	Kaminski, Henry J: 5 articles (11/2020 - 01/2008)
2.	Ströbel, Philipp: 5 articles (11/2020 - 12/2012)
3.	Wolfe, Gil I: 5 articles (11/2020 - 01/2008)
4.	Yoshikawa, Hiroaki: 4 articles (11/2020 - 11/2007)
5.	Marx, Alexander: 4 articles (01/2019 - 12/2012)
6.	Aban, Inmaculada B: 3 articles (11/2020 - 01/2018)
7.	Conwit, Robin: 3 articles (11/2020 - 01/2008)
8.	Minisman, Greg: 3 articles (11/2020 - 01/2008)
9.	Nix, Wilfred: 3 articles (11/2020 - 12/2012)
10.	Weis, Cleo-Aron: 3 articles (05/2018 - 01/2018)

Related Diseases

1.	Myasthenia Gravis 01/01/2022 - "Die Veröffentlichung des MGTX-Trials 2016 im New England Journal of Medicine lieferte die ersten randomisiert-kontrollierten Daten, nach denen Patienten mit Acetylcholin-Rezeptor-Antikörper-positiver generalisierter Myasthenia gravis im Alter von 18 bis 65 Jahren von der chirurgischen Resektion des Thymus über eine mediane Sternotomie profitieren. " 09/01/2019 - "Since MGTX trial revealed the significant efficacy of thymectomy in myasthenia gravis patients aged up to 65, the number of patients having operative indication may increase. " 01/01/2020 - "Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study." 09/01/2019 - "MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis." 01/01/2018 - "Challenging the current model of early-onset myasthenia gravis pathogenesis in the light of the MGTX trial and histological heterogeneity of thymectomy specimens."
2.	Pancreatic Neoplasms (Pancreatic Cancer) 03/01/2011 - "mGTX demonstrates acceptable tolerability with interesting activity in patients with pancreatic cancer. " 03/01/2011 - "We report the first prospective analysis of the 3-drug combination of gemcitabine (G), docetaxel (T) and capecitabine (X) (mGTX) with schedule modification to maximize biomodulation of X. We conducted a dose escalation study of mGTX in first-line treatment of metastatic pancreas cancer using three dose levels (DL 1-3). "
3.	Stroke (Strokes) 01/01/2008 - "The National Institute for Neurological Disorders and Stroke awarded funding for MGTX in September 2005, and NIH awarded funding for the ancillary Biomarkers study (BioMG) in February 2006. "
4.	Thymoma (Thymic Carcinoma) 11/01/2020 - "MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody-positive MG without thymoma. "
5.	Nervous System Diseases (Neurological Disorders) 01/01/2008 - "The National Institute for Neurological Disorders and Stroke awarded funding for MGTX in September 2005, and NIH awarded funding for the ancillary Biomarkers study (BioMG) in February 2006. "

Related Drugs and Biologics

1.	Cholinergic Receptors
2.	Gemcitabine
3.	Docetaxel (Taxotere)
4.	Capecitabine (Xeloda)
5.	Prednisone (Sone)
6.	Biomarkers (Surrogate Marker)
7.	Antibodies
8.	MicroRNAs (MicroRNA)
9.	Autoantibodies
10.	margatoxin

Related Therapies and Procedures

1.	Thymectomy
2.	Therapeutics
3.	Sternotomy
4.	Activities of Daily Living (ADL)